NCT06966700 2026-04-17A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Merck Sharp & Dohme LLCPhase 3 Recruiting2,400 enrolled
NCT07441460 2026-04-08A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerShanghai JMT-Bio Inc.Phase 3 Recruiting1,800 enrolled